{"ticker": {"uuid": "820505f9-1df6-44d2-a829-e12414cbe966", "symbol": "PYPD", "name": "PolyPid", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "PolyPid Ltd. (PYPD) boosts option pool by 1.5M shares and clears CEO grant", "summary": "PolyPid Ltd. (PYPD) held its Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, where all four proposals were approved, including the re-election of auditors and directors, amendments to non-executive directors' option grants, and an option grant for CEO D", "url": "https://www.stocktitan.net/sec-filings/PYPD/6-k-poly-pid-ltd-current-report-foreign-issuer-6db9643ce351.html", "source_name": "Stock Titan", "published_at": "2026-07-15T19:40:49", "published_display": "15 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid (PYPD) Climbs 3.97% as Shares Test Key Resistance Zone - AI Trade Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOTnRfTW1xUVJGaWtNY1B0NkJveDBUTGlGUnNCaEhkWE1iQ09RY2FWVmNZNGpiZUxDYVVjdTNFZXlKVlN4Q0Zvdi1lNjZDNDJFdlN6TWd1Wl8wUEUxV05ldEFIQjJQcDRzclBHLVVhU3ZHaklLQjhLWGpJV2dGWm1KeUw5ZmNZMGxpUVNhTlBJc0JRVVVSSUo1c2hvcGl5MzdsOWEwZA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-14T16:37:07+00:00", "published_display": "14 Jul 2026 16:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PolyPid (PYPD) Lytham Partners Spring 2026 Investor Conference Summary", "summary": "PolyPid (PYPD) presented at the Lytham Partners Spring 2026 Investor Conference, highlighting key milestones for D-PLEX100. These include the recent NDA submission, anticipated FDA acceptance, and plans for EU MAA submission in 2027. The company also emphasized the strong clinica", "url": "https://quartr.com/events/polypid-ltd-pypd-lytham-partners-spring-2026-investor-conference_FeqDZGYx", "source_name": "Quartr", "published_at": "2026-07-09T16:40:19", "published_display": "09 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid (PYPD) The Citizens Life Sciences Conference 2026 Summary", "summary": "PolyPid (PYPD) provided an update on its D-PLEX\u2081\u2080\u2080 drug at The Citizens Life Sciences Conference 2026, highlighting the imminent NDA submission and Breakthrough Therapy Designation. The drug demonstrated significant reduction in surgical site infections in Phase 3 trials and aims", "url": "https://quartr.com/events/polypid-pypd-the-citizens-life-sciences-conference-2026_FeqD5mgb", "source_name": "Quartr", "published_at": "2026-07-09T16:40:19", "published_display": "09 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of PolyPid Ltd. \u2013 NASDAQ:PYPD", "summary": "This article displays the \"Price to earnings forward\" metric for PolyPid Ltd. under the NASDAQ:PYPD ticker. It presents a simple table showing the period, value, change, and change percentage, although no actual data is provided in the content. The page also includes standard mar", "url": "https://www.tradingview.com/symbols/NASDAQ-PYPD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T08:10:03", "published_display": "04 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd stock and its pipeline. A closer look at the drug-delivery specialist", "summary": "PolyPid Ltd is a clinical-stage biopharmaceutical company specializing in localized, extended-release drug-delivery solutions for surgical patients, aiming to reduce systemic exposure while maintaining effective local drug concentrations. The company's stock reflects investor int", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/polypid-ltd-stock-and-its-pipeline-a-closer-look-at-the-drug-delivery/69682756", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T19:41:22", "published_display": "03 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PYPD - Polypid Ltd Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Polypid Ltd (PYPD). It details the company's stock performance, key financial metrics such as market cap, income, sales, and employee count, as well as various valuation ratios, efficiency ratios, a", "url": "https://finviz.com/stock?t=PYPD&ta=1&p=w&ty=lf&b=1", "source_name": "Finviz", "published_at": "2026-07-02T06:39:14", "published_display": "02 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of PolyPid Ltd. \u2013 NASDAQ:PYPD", "summary": "This article provides the \"Price to book forward\" financial metric for PolyPid Ltd. (NASDAQ: PYPD). The data is presented simply as \"Period\", \"Value\", \"Change\", and \"Change %\". No specific values for these metrics are displayed in the provided content.", "url": "https://www.tradingview.com/symbols/NASDAQ-PYPD/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T05:39:14", "published_display": "02 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of PolyPid Ltd. \u2013 NASDAQ:PYPD", "summary": "This article provides financial context on PolyPid Ltd. (NASDAQ: PYPD), specifically focusing on its enterprise value to EBITDA forward metric. It appears to be an excerpt from a financial data platform, likely TradingView, presenting a snapshot of the metric's period, value, and", "url": "https://www.tradingview.com/symbols/NASDAQ-PYPD/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T03:09:27", "published_display": "02 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd. Actuals & Estimates (NASDAQ:PYPD)", "summary": "This article provides an overview of PolyPid Ltd. (NASDAQ:PYPD) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, volatility, market capitalization, upcoming earnings dates, and past financial results like rev", "url": "https://www.tradingview.com/symbols/NASDAQ-PYPD/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T02:40:07", "published_display": "27 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "2PV Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for PolyPid Ltd. (2PV) stock, based on analyst opinions. It details the company's price target, historical stock performance including all-time high and low prices, earnings reports, revenue, net income, and employee count. Additionally, it confir", "url": "https://www.tradingview.com/symbols/FWB-2PV/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:12:09", "published_display": "26 Jun 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of PolyPid Ltd (PYPD), including its support and resistance levels, various technical indicators, and moving averages. According to the analysis, the overall signal based on moving averages and other technical indicators is \"Sell,\" with ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pypd/technical", "source_name": "TradingKey", "published_at": "2026-06-25T14:12:09", "published_display": "25 Jun 2026 14:12", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a historical overview of PolyPid Ltd (PYPD) dividend payouts and stock split events. It indicates that PolyPid Ltd has not distributed any dividends over the past five years. The only major stock split event listed is a 30-to-1 merger that occurred on August", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pypd/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T13:11:11", "published_display": "19 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of PolyPid Ltd (PYPD), listing its major shareholders and institutional holdings. Key shareholders include Aurum Ventures M.K.I., Rodney Hodges, and Centaurus Investments Limited, among others. The report also breaks down shareholder", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pypd/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T22:39:02", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for PolyPid Ltd (PYPD), detailing its business segments, regional revenue, and profit contribution. The report indicates that relevant data for these categories have not yet been disclosed by the company. The article also ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pypd/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T21:10:16", "published_display": "18 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE9YbFNXOWlQaGE4eGYwdFRpQzdMSE95cW9oWGZMR2dfRHpocVhBNmxzcGo2RUFVeWV6ZkI3RXNLbTBLT29FMjVEbXhHWW1MTEI1ZjRSa3BFNW55RGVuSGdvcVRwTzFnMmFBZmN4UmZFaw?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T09:23:10+00:00", "published_display": "18 Jun 2026 09:23", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of PolyPid Ltd's (PYPD) financial health, focusing on its profitability and balance sheet. It highlights that relevant financial data regarding cash and cash equivalents, total assets, liabilities, free cash flow, revenue, operating profit, and o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pypd/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T10:17:59", "published_display": "18 Jun 2026 10:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Institutional Confidence", "summary": "This article from TradingKey provides an overview of PolyPid Ltd's (PYPD) institutional confidence, focusing on changes in shareholdings by various institutional investors. Key data points displayed include the number of shares held and the percentage change for each listed insti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pypd/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:16", "published_display": "18 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for PolyPid Ltd (PYPD), focusing on its volatility, financial metrics, and investment risk. It details various risk indicators such as Beta, VaR, Maximum Drawdown, Volatility, and Sharpe Ratio over different time frames, offering investors ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pypd/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T09:17:59", "published_display": "18 Jun 2026 09:17", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd Stock (US70450B1035): modest move as market awaits next catalyst", "summary": "PolyPid Ltd (PYPD) stock experienced minimal price changes recently, closing at $4.67 after a slight gain of 0.97%. The clinical-stage biopharmaceutical company remains a speculative micro-cap, with investors anticipating future clinical, regulatory, or financing updates as major", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/polypid-ltd-stock-us70450b1035-modest-move-as-market-awaits-next/69557098", "source_name": "AD HOC NEWS", "published_at": "2026-06-16T22:10:33", "published_display": "16 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd. (PYPD) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for PolyPid Ltd. (PYPD) stock. It shows the current stock price, recent price change, and links to real-time quotes. The article mentions that there is no current analyst rating or earnings information for PolyPid Ltd.", "url": "https://stockstotrade.com/quote/PYPD", "source_name": "StocksToTrade", "published_at": "2026-06-16T11:39:02", "published_display": "16 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PYPD Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for PolyPid Ltd (PYPD), indicating an overall \"Strong Buy\" consensus based on various technical indicators and moving averages. It details momentum indicators like RSI and MACD, as well as crucial support and res", "url": "https://intellectia.ai/en/stock/PYPD/technical", "source_name": "Intellectia AI", "published_at": "2026-06-11T20:39:34", "published_display": "11 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid schedules annual and extraordinary shareholder meeting for July 15 By Investing.com", "summary": "PolyPid Ltd. (NASDAQ:PYPD) announced it will hold its Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, at its headquarters in Petach Tikva, Israel. Shareholders of record as of June 15, 2026, will be eligible to vote. The meeting details, including the a", "url": "https://ng.investing.com/news/sec-filings/polypid-schedules-annual-and-extraordinary-shareholder-meeting-for-july-15-93CH-2552701", "source_name": "Investing.com Nigeria", "published_at": "2026-06-10T21:12:27", "published_display": "10 Jun 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid schedules annual and extraordinary shareholder meeting for July 15", "summary": "PolyPid Ltd. (NASDAQ:PYPD) has announced that it will hold its Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, at its headquarters in Petach Tikva, Israel. Shareholders of record by June 15, 2026, will be eligible to receive notice and vote at the meeti", "url": "https://www.investing.com/news/sec-filings/polypid-schedules-annual-and-extraordinary-shareholder-meeting-for-july-15-93CH-4736069", "source_name": "Investing.com", "published_at": "2026-06-10T20:39:34", "published_display": "10 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] PolyPid Ltd. Current Report (Foreign Issuer) | PYPD SEC Filing - Form 6-K", "summary": "PolyPid Ltd. has scheduled an annual and extraordinary general meeting for shareholders on July 15, 2026, in Petach Tikva, Israel. The meeting will address proposals to re-elect independent auditors Kost Forer Gabbay & Kasierer (EY), re-elect eight directors and approve their com", "url": "https://www.stocktitan.net/sec-filings/PYPD/6-k-poly-pid-ltd-current-report-foreign-issuer-4f03f48f07a2.html", "source_name": "Stock Titan", "published_at": "2026-06-10T20:10:02", "published_display": "10 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Can We Expect A Profit From PolyPid Ltd. (NASDAQ:PYPD)?", "summary": "PolyPid Ltd. (NASDAQ:PYPD), a biopharmaceutical company with an US$86m market cap, is projected by analysts to achieve profitability around 2028. The company reported a US$34m loss in its last financial year but is expected to break even in approximately two years, requiring an a", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pypd/polypid/news/when-can-we-expect-a-profit-from-polypid-ltd-nasdaqpypd", "source_name": "Simply Wall Street", "published_at": "2026-06-08T10:09:36", "published_display": "08 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd. (PYPD) Shares Slide 6.8% as Stock Approaches Key Support at $4.27 - Market Cap Weight", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOSDVNcTljelZyblM1d0dmcW0xQlBCZExqdWZOSnlYNzFiZ2UyTU1UZGRrc18zaUxXOXdKN1hIbVY3RFpHa3FVdWpraE1CMkZzSFpURllnQ2xsQjBicVNwQS14VVV6Q2lESmMtWmVtTFJWRkFuTFA4Z1FueVBZSGFhbVJNam5qbEVoUE1QT25hVWViczhVN1NQWm5PcXdyVjVDZWk1UmwzbU1HVnh0M3piRXRjenRIbDFZcEpxQQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Completes New Drug Application Submission to FDA for D-PLEX\u2081\u2080\u2080", "summary": "PolyPid Ltd. has completed its New Drug Application (NDA) submission to the FDA for D-PLEX\u2081\u2080\u2080, a drug designed to prevent surgical site infections during colorectal surgery. The submission is supported by positive Phase 3 trial results showing a 60% relative risk reduction in inf", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polypid-completes-drug-application-submission-123000954.html", "source_name": "Market source", "published_at": "2026-06-01T17:09:10", "published_display": "01 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Completes Rolling NDA Submission to FDA for D-PLEX100", "summary": "PolyPid Ltd. has finished its rolling New Drug Application (NDA) submission to the FDA for D-PLEX100, a drug designed to improve surgical outcomes by providing controlled, continuous delivery of medicines. The company, a clinical-stage biopharmaceutical firm based in Israel, conc", "url": "https://www.marketscreener.com/news/polypid-completes-rolling-nda-submission-to-fda-for-d-plex100-ce7f5dd9db88f126", "source_name": "marketscreener.com", "published_at": "2026-06-01T17:09:10", "published_display": "01 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid completes NDA submission for surgical infection drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOMHAwLXU2cHoyc3VVMGtBYTlOWmxZS1ZzSnNiYldlR3JlMXc5TmtBbTJDNzdKTnRoMDNURW5kRzNZRU5ranZFajZjbUs4cjZDa1lJTW5Qa1B6Z3hRYTVCNEhlcm5LV3dZNTFOWDF2NWV2X1RLdTlrTW1KYnp3c3JkSEp1eHBsc1BxR0ZqLS1xa1ZScGh3NHhvcTF6OHdaQVlEdjdaemF5S2ZUSGprNmNEM2dBRXBxcE9h?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New surgical infection drug from PolyPid heads to FDA decision in 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxORHlidGYwdVhOVWJXQU9NT01iMTZkdGJYWlp0MTh4YWZFbUxiUGlpMG5JcnBDNDlWZVdRTkZlWDhBQzVjY1BmZHN2MXExNUpxUS1PWkZTT1BCOXdmYk40THFXbDJXc0RRRVNNTjEtamgyLUxQa0RjZ25LWFpBZUotdGVOSTNUYWFaQ0FJQWZKLVR6aWhKbTNxcFBvNXVjckYxSlJDVWtrWVp5bjNkZWQzeF94X3JmazF6V0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polypid-participate-craig-hallum-23rd-123000907.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T12:30:00+00:00", "published_display": "20 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polypid-ltd-pypd-q1-2026-230113482.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T23:01:13+00:00", "published_display": "13 May 2026 23:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/5175bac4-f3d5-3be1-8f65-9d6bd2e756c4/polypid-ltd.-q1-2026-earnings.html", "source_name": "Moby", "published_at": "2026-05-13T20:58:19+00:00", "published_display": "13 May 2026 20:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid (PYPD) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/23a07c6e-55c0-3bbc-933e-c2346d9bec57/polypid-%28pypd%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-13T19:01:43+00:00", "published_display": "13 May 2026 19:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Q1 2026 Earnings Call: Complete Transcript", "summary": "", "url": "https://finance.yahoo.com/news/polypid-q1-2026-earnings-call-132439720.html", "source_name": "Benzinga", "published_at": "2026-05-13T13:24:39+00:00", "published_display": "13 May 2026 13:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: PolyPid\u2019s Q1 2026 earnings beat expectations, stock rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPc0hIOWtKWGVrNy1DY0lJWkNMekt4Z2E0aEdNcGMyc3lYNHRtTG4wZGI0X19FQTc3OV9ZZFI5NkJ5MDdCUXZDMzVYclR3M29vNWpoc0JVUk1tMGc3Qzk0V1YybzU1dEpLMzZMME9UTFR2aTZPSjdsbEtjTi04MHlrSjdieGZJUWRsY3hqT1h1VThrRlZSVDd5Q09TTEZlNUM4R0lhMV9fWjlzTTBHWnBDX3ZZZVNHUml4NnExTFdtbEthNy12WGxYSXFTV1RhazRQQ1E?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZFNvM3NtQzY1RC02dWRTOURMaFJOSFM1OFI1NVVST0dwdzI0Mnp6N2ZQblFoSEF2YkhJdzlPdl9uQ3JnZGpNNDFqTmhRNk43a2pMMkptNUNsV2JVbk4xa0tYOHRjRDhsaWpPVWNCRGVsLUZKUUFzaFpaSEFxTHQ0aG5tTVVSdm44dlBGZnFPOG9Ea0RpVTRiTDhOam4?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxQXzVFelBtQlQ3MUdZMnhPOENxNmItNUZESHNzVHJvY1YydDI2WnpKYnp1VUlZUWliek1wQzZ2b0FiZ1MzbkVJZFZILTlCZHhJOExPeERDX3IzYlhLS1I4MTBKbmQzc0psZFlIOWZXelJhSlVTX0tuTVBTeVA3aHdLUUp4ZmRFb2hyX3NDSzlIOS1SSVpnOVVvMThLYml5Y1laRUszR3hQM3BjcGJqNFJfbk5JS1FIMGo3MEs1NWRobl9GZWVhMW5JVVh6UFVjcmZtdnhiaTJFOE1sSm03MkVvUlo4WkdKRU05UEE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxOUktxZ1FTOVB0cUZ5X19WZEx0Z2FhSzAtbFp2VDVYQU9EOS1nSUJ4anR6bTFmOXBXZWJ2aFhsV2NBV09ZRHhWVTVrejZYam5idmJNRnhNSURKN3RzYU1BR1lLTmpHTFg4Z0M4Yi1uN1gxWHllWFFzTHJzR3gtanp3cXZSbE5PMkVYNDFzaU9DVTJYMU5sQkw5T2dKRG1vbHd4ekU4UWFaUEcwdnJJSHp1QngxY284cS1DMTNRS2hQQ2VBeHM4RnhNZzJxMk5pYW1KZHFUa3hyOXl3bWUtZXVfQ0dMekZRaFJFVVRHQ2dnbGQ2YU51em9RbGhDbjQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurum holds 5,001,561 shares in Polypid Ltd. (PYPD) with exercisable warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPQlBiX0Z5WWMycWtMQjJfTVJVaWR4ZVBlczRHMVFTckt2SzBmY282Ykg0OEd5dkRjOXAtNXVZdU1uUHdId2NVQnVBWklJNHEyUXJROXlsMzBLUVhqUmY5QkR0YlFwdmdvRmhGdUZDMEFRX1lqUkh1Rk5GaktIbFNKSHBsYWVFS0NUUEFlanF4ckhjUUhqVVl2a1BOYzZvYUU1aGlaV21SQ3pvNkJ4WjlxZWZjdGtRQ3RZSjl3LXZMS3hGTHA4bGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "When Will PolyPid Ltd. (NASDAQ:PYPD) Turn A Profit?", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBBTTdlZFNRVkdsQk9JQnpPQ0JNeXpVd09YaWJhQ2R2SVdvNC1pd1F3UkFUbGkzNUUxTUhZMWNTRmpKVTRRZUw1ZlB3NlJ2X1hKU3R6MnZvdjkzeEJMVWZXQWFtenNNaUxtQThLdDJpTGdOY2RsOWVVNlFOZGFoRmM?oc=5", "source_name": "Market source", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is PolyPid (NASDAQ:PYPD) A Risky Investment?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-28T07:00:00+00:00", "published_display": "28 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analyst Says PolyPid is a Buy with 300% Potential Upside as it nears Phase 3 Data Readout", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxQSVlQM2VrM192NnRnWmNhdEFzTFEyMzE1eDlQWlhqb3paWXliY1ZwWUJyQUw1dFVCWlVDR0xfRlpOemxCZG9pb3JJbEpGWUM2dVdFZk5DSlUtWjkzVzFsNURQY2dpQjc2R0dLdlVtY01qS29oYW9jMkotTUlZVzlWN18xdk0yZjlONXZVdWRrM3lQelpoYVB0X1NnWUxrNFB6czlvQzVZcFlxMVROMzlDVGRFbjZuQk52VElXelR2bHdZVGoyRWF2Z2pleDJGX05PQnBTVWw1YjVTUjFwMFBqYU9URHgzc2dNRVFR?oc=5", "source_name": "newsblaze.com", "published_at": "2025-06-02T07:00:00+00:00", "published_display": "02 Jun 2025 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid (PYPD) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE84ZklLRnF5QkdlMW5WUEFpaGN6anF5WEJFRHI4OHlOa3FxN0hGYURWWUk1T1d6NlprQWVfd2RMQkxOQU5JaTllNmluZy1tNjJWNnoxUlEwQmRxdw?oc=5", "source_name": "MarketBeat", "published_at": "2020-07-21T12:59:37+00:00", "published_display": "21 Jul 2020 12:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "PolyPid Ltd. (PYPD) boosts option pool by 1.5M shares and clears CEO grant", "summary": "PolyPid Ltd. (PYPD) held its Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, where all four proposals were approved, including the re-election of auditors and directors, amendments to non-executive directors' option grants, and an option grant for CEO D", "url": "https://www.stocktitan.net/sec-filings/PYPD/6-k-poly-pid-ltd-current-report-foreign-issuer-6db9643ce351.html", "source_name": "Stock Titan", "published_at": "2026-07-15T19:40:49", "published_display": "15 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid (PYPD) Climbs 3.97% as Shares Test Key Resistance Zone - AI Trade Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOTnRfTW1xUVJGaWtNY1B0NkJveDBUTGlGUnNCaEhkWE1iQ09RY2FWVmNZNGpiZUxDYVVjdTNFZXlKVlN4Q0Zvdi1lNjZDNDJFdlN6TWd1Wl8wUEUxV05ldEFIQjJQcDRzclBHLVVhU3ZHaklLQjhLWGpJV2dGWm1KeUw5ZmNZMGxpUVNhTlBJc0JRVVVSSUo1c2hvcGl5MzdsOWEwZA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-14T16:37:07+00:00", "published_display": "14 Jul 2026 16:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid (PYPD) Lytham Partners Spring 2026 Investor Conference Summary", "summary": "PolyPid (PYPD) presented at the Lytham Partners Spring 2026 Investor Conference, highlighting key milestones for D-PLEX100. These include the recent NDA submission, anticipated FDA acceptance, and plans for EU MAA submission in 2027. The company also emphasized the strong clinica", "url": "https://quartr.com/events/polypid-ltd-pypd-lytham-partners-spring-2026-investor-conference_FeqDZGYx", "source_name": "Quartr", "published_at": "2026-07-09T16:40:19", "published_display": "09 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid (PYPD) The Citizens Life Sciences Conference 2026 Summary", "summary": "PolyPid (PYPD) provided an update on its D-PLEX\u2081\u2080\u2080 drug at The Citizens Life Sciences Conference 2026, highlighting the imminent NDA submission and Breakthrough Therapy Designation. The drug demonstrated significant reduction in surgical site infections in Phase 3 trials and aims", "url": "https://quartr.com/events/polypid-pypd-the-citizens-life-sciences-conference-2026_FeqD5mgb", "source_name": "Quartr", "published_at": "2026-07-09T16:40:19", "published_display": "09 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of PolyPid Ltd. \u2013 NASDAQ:PYPD", "summary": "This article displays the \"Price to earnings forward\" metric for PolyPid Ltd. under the NASDAQ:PYPD ticker. It presents a simple table showing the period, value, change, and change percentage, although no actual data is provided in the content. The page also includes standard mar", "url": "https://www.tradingview.com/symbols/NASDAQ-PYPD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T08:10:03", "published_display": "04 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd stock and its pipeline. A closer look at the drug-delivery specialist", "summary": "PolyPid Ltd is a clinical-stage biopharmaceutical company specializing in localized, extended-release drug-delivery solutions for surgical patients, aiming to reduce systemic exposure while maintaining effective local drug concentrations. The company's stock reflects investor int", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/polypid-ltd-stock-and-its-pipeline-a-closer-look-at-the-drug-delivery/69682756", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T19:41:22", "published_display": "03 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PYPD - Polypid Ltd Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Polypid Ltd (PYPD). It details the company's stock performance, key financial metrics such as market cap, income, sales, and employee count, as well as various valuation ratios, efficiency ratios, a", "url": "https://finviz.com/stock?t=PYPD&ta=1&p=w&ty=lf&b=1", "source_name": "Finviz", "published_at": "2026-07-02T06:39:14", "published_display": "02 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of PolyPid Ltd. \u2013 NASDAQ:PYPD", "summary": "This article provides the \"Price to book forward\" financial metric for PolyPid Ltd. (NASDAQ: PYPD). The data is presented simply as \"Period\", \"Value\", \"Change\", and \"Change %\". No specific values for these metrics are displayed in the provided content.", "url": "https://www.tradingview.com/symbols/NASDAQ-PYPD/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T05:39:14", "published_display": "02 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of PolyPid Ltd. \u2013 NASDAQ:PYPD", "summary": "This article provides financial context on PolyPid Ltd. (NASDAQ: PYPD), specifically focusing on its enterprise value to EBITDA forward metric. It appears to be an excerpt from a financial data platform, likely TradingView, presenting a snapshot of the metric's period, value, and", "url": "https://www.tradingview.com/symbols/NASDAQ-PYPD/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T03:09:27", "published_display": "02 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd. Actuals & Estimates (NASDAQ:PYPD)", "summary": "This article provides an overview of PolyPid Ltd. (NASDAQ:PYPD) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, volatility, market capitalization, upcoming earnings dates, and past financial results like rev", "url": "https://www.tradingview.com/symbols/NASDAQ-PYPD/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T02:40:07", "published_display": "27 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "2PV Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for PolyPid Ltd. (2PV) stock, based on analyst opinions. It details the company's price target, historical stock performance including all-time high and low prices, earnings reports, revenue, net income, and employee count. Additionally, it confir", "url": "https://www.tradingview.com/symbols/FWB-2PV/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:12:09", "published_display": "26 Jun 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of PolyPid Ltd (PYPD), including its support and resistance levels, various technical indicators, and moving averages. According to the analysis, the overall signal based on moving averages and other technical indicators is \"Sell,\" with ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pypd/technical", "source_name": "TradingKey", "published_at": "2026-06-25T14:12:09", "published_display": "25 Jun 2026 14:12", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a historical overview of PolyPid Ltd (PYPD) dividend payouts and stock split events. It indicates that PolyPid Ltd has not distributed any dividends over the past five years. The only major stock split event listed is a 30-to-1 merger that occurred on August", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pypd/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T13:11:11", "published_display": "19 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of PolyPid Ltd (PYPD), listing its major shareholders and institutional holdings. Key shareholders include Aurum Ventures M.K.I., Rodney Hodges, and Centaurus Investments Limited, among others. The report also breaks down shareholder", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pypd/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T22:39:02", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for PolyPid Ltd (PYPD), detailing its business segments, regional revenue, and profit contribution. The report indicates that relevant data for these categories have not yet been disclosed by the company. The article also ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pypd/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T21:10:16", "published_display": "18 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE9YbFNXOWlQaGE4eGYwdFRpQzdMSE95cW9oWGZMR2dfRHpocVhBNmxzcGo2RUFVeWV6ZkI3RXNLbTBLT29FMjVEbXhHWW1MTEI1ZjRSa3BFNW55RGVuSGdvcVRwTzFnMmFBZmN4UmZFaw?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T09:23:10+00:00", "published_display": "18 Jun 2026 09:23", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of PolyPid Ltd's (PYPD) financial health, focusing on its profitability and balance sheet. It highlights that relevant financial data regarding cash and cash equivalents, total assets, liabilities, free cash flow, revenue, operating profit, and o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pypd/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T10:17:59", "published_display": "18 Jun 2026 10:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Institutional Confidence", "summary": "This article from TradingKey provides an overview of PolyPid Ltd's (PYPD) institutional confidence, focusing on changes in shareholdings by various institutional investors. Key data points displayed include the number of shares held and the percentage change for each listed insti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pypd/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:16", "published_display": "18 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for PolyPid Ltd (PYPD), focusing on its volatility, financial metrics, and investment risk. It details various risk indicators such as Beta, VaR, Maximum Drawdown, Volatility, and Sharpe Ratio over different time frames, offering investors ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pypd/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T09:17:59", "published_display": "18 Jun 2026 09:17", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd Stock (US70450B1035): modest move as market awaits next catalyst", "summary": "PolyPid Ltd (PYPD) stock experienced minimal price changes recently, closing at $4.67 after a slight gain of 0.97%. The clinical-stage biopharmaceutical company remains a speculative micro-cap, with investors anticipating future clinical, regulatory, or financing updates as major", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/polypid-ltd-stock-us70450b1035-modest-move-as-market-awaits-next/69557098", "source_name": "AD HOC NEWS", "published_at": "2026-06-16T22:10:33", "published_display": "16 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd. (PYPD) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for PolyPid Ltd. (PYPD) stock. It shows the current stock price, recent price change, and links to real-time quotes. The article mentions that there is no current analyst rating or earnings information for PolyPid Ltd.", "url": "https://stockstotrade.com/quote/PYPD", "source_name": "StocksToTrade", "published_at": "2026-06-16T11:39:02", "published_display": "16 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PYPD Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for PolyPid Ltd (PYPD), indicating an overall \"Strong Buy\" consensus based on various technical indicators and moving averages. It details momentum indicators like RSI and MACD, as well as crucial support and res", "url": "https://intellectia.ai/en/stock/PYPD/technical", "source_name": "Intellectia AI", "published_at": "2026-06-11T20:39:34", "published_display": "11 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid schedules annual and extraordinary shareholder meeting for July 15 By Investing.com", "summary": "PolyPid Ltd. (NASDAQ:PYPD) announced it will hold its Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, at its headquarters in Petach Tikva, Israel. Shareholders of record as of June 15, 2026, will be eligible to vote. The meeting details, including the a", "url": "https://ng.investing.com/news/sec-filings/polypid-schedules-annual-and-extraordinary-shareholder-meeting-for-july-15-93CH-2552701", "source_name": "Investing.com Nigeria", "published_at": "2026-06-10T21:12:27", "published_display": "10 Jun 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid schedules annual and extraordinary shareholder meeting for July 15", "summary": "PolyPid Ltd. (NASDAQ:PYPD) has announced that it will hold its Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, at its headquarters in Petach Tikva, Israel. Shareholders of record by June 15, 2026, will be eligible to receive notice and vote at the meeti", "url": "https://www.investing.com/news/sec-filings/polypid-schedules-annual-and-extraordinary-shareholder-meeting-for-july-15-93CH-4736069", "source_name": "Investing.com", "published_at": "2026-06-10T20:39:34", "published_display": "10 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] PolyPid Ltd. Current Report (Foreign Issuer) | PYPD SEC Filing - Form 6-K", "summary": "PolyPid Ltd. has scheduled an annual and extraordinary general meeting for shareholders on July 15, 2026, in Petach Tikva, Israel. The meeting will address proposals to re-elect independent auditors Kost Forer Gabbay & Kasierer (EY), re-elect eight directors and approve their com", "url": "https://www.stocktitan.net/sec-filings/PYPD/6-k-poly-pid-ltd-current-report-foreign-issuer-4f03f48f07a2.html", "source_name": "Stock Titan", "published_at": "2026-06-10T20:10:02", "published_display": "10 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Can We Expect A Profit From PolyPid Ltd. (NASDAQ:PYPD)?", "summary": "PolyPid Ltd. (NASDAQ:PYPD), a biopharmaceutical company with an US$86m market cap, is projected by analysts to achieve profitability around 2028. The company reported a US$34m loss in its last financial year but is expected to break even in approximately two years, requiring an a", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pypd/polypid/news/when-can-we-expect-a-profit-from-polypid-ltd-nasdaqpypd", "source_name": "Simply Wall Street", "published_at": "2026-06-08T10:09:36", "published_display": "08 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd. (PYPD) Shares Slide 6.8% as Stock Approaches Key Support at $4.27 - Market Cap Weight", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOSDVNcTljelZyblM1d0dmcW0xQlBCZExqdWZOSnlYNzFiZ2UyTU1UZGRrc18zaUxXOXdKN1hIbVY3RFpHa3FVdWpraE1CMkZzSFpURllnQ2xsQjBicVNwQS14VVV6Q2lESmMtWmVtTFJWRkFuTFA4Z1FueVBZSGFhbVJNam5qbEVoUE1QT25hVWViczhVN1NQWm5PcXdyVjVDZWk1UmwzbU1HVnh0M3piRXRjenRIbDFZcEpxQQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Completes New Drug Application Submission to FDA for D-PLEX\u2081\u2080\u2080", "summary": "PolyPid Ltd. has completed its New Drug Application (NDA) submission to the FDA for D-PLEX\u2081\u2080\u2080, a drug designed to prevent surgical site infections during colorectal surgery. The submission is supported by positive Phase 3 trial results showing a 60% relative risk reduction in inf", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polypid-completes-drug-application-submission-123000954.html", "source_name": "Market source", "published_at": "2026-06-01T17:09:10", "published_display": "01 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Completes Rolling NDA Submission to FDA for D-PLEX100", "summary": "PolyPid Ltd. has finished its rolling New Drug Application (NDA) submission to the FDA for D-PLEX100, a drug designed to improve surgical outcomes by providing controlled, continuous delivery of medicines. The company, a clinical-stage biopharmaceutical firm based in Israel, conc", "url": "https://www.marketscreener.com/news/polypid-completes-rolling-nda-submission-to-fda-for-d-plex100-ce7f5dd9db88f126", "source_name": "marketscreener.com", "published_at": "2026-06-01T17:09:10", "published_display": "01 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid completes NDA submission for surgical infection drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOMHAwLXU2cHoyc3VVMGtBYTlOWmxZS1ZzSnNiYldlR3JlMXc5TmtBbTJDNzdKTnRoMDNURW5kRzNZRU5ranZFajZjbUs4cjZDa1lJTW5Qa1B6Z3hRYTVCNEhlcm5LV3dZNTFOWDF2NWV2X1RLdTlrTW1KYnp3c3JkSEp1eHBsc1BxR0ZqLS1xa1ZScGh3NHhvcTF6OHdaQVlEdjdaemF5S2ZUSGprNmNEM2dBRXBxcE9h?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New surgical infection drug from PolyPid heads to FDA decision in 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxORHlidGYwdVhOVWJXQU9NT01iMTZkdGJYWlp0MTh4YWZFbUxiUGlpMG5JcnBDNDlWZVdRTkZlWDhBQzVjY1BmZHN2MXExNUpxUS1PWkZTT1BCOXdmYk40THFXbDJXc0RRRVNNTjEtamgyLUxQa0RjZ25LWFpBZUotdGVOSTNUYWFaQ0FJQWZKLVR6aWhKbTNxcFBvNXVjckYxSlJDVWtrWVp5bjNkZWQzeF94X3JmazF6V0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polypid-participate-craig-hallum-23rd-123000907.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T12:30:00+00:00", "published_display": "20 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polypid-ltd-pypd-q1-2026-230113482.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T23:01:13+00:00", "published_display": "13 May 2026 23:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Ltd. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/5175bac4-f3d5-3be1-8f65-9d6bd2e756c4/polypid-ltd.-q1-2026-earnings.html", "source_name": "Moby", "published_at": "2026-05-13T20:58:19+00:00", "published_display": "13 May 2026 20:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid (PYPD) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/23a07c6e-55c0-3bbc-933e-c2346d9bec57/polypid-%28pypd%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-13T19:01:43+00:00", "published_display": "13 May 2026 19:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Q1 2026 Earnings Call: Complete Transcript", "summary": "", "url": "https://finance.yahoo.com/news/polypid-q1-2026-earnings-call-132439720.html", "source_name": "Benzinga", "published_at": "2026-05-13T13:24:39+00:00", "published_display": "13 May 2026 13:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: PolyPid\u2019s Q1 2026 earnings beat expectations, stock rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPc0hIOWtKWGVrNy1DY0lJWkNMekt4Z2E0aEdNcGMyc3lYNHRtTG4wZGI0X19FQTc3OV9ZZFI5NkJ5MDdCUXZDMzVYclR3M29vNWpoc0JVUk1tMGc3Qzk0V1YybzU1dEpLMzZMME9UTFR2aTZPSjdsbEtjTi04MHlrSjdieGZJUWRsY3hqT1h1VThrRlZSVDd5Q09TTEZlNUM4R0lhMV9fWjlzTTBHWnBDX3ZZZVNHUml4NnExTFdtbEthNy12WGxYSXFTV1RhazRQQ1E?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZFNvM3NtQzY1RC02dWRTOURMaFJOSFM1OFI1NVVST0dwdzI0Mnp6N2ZQblFoSEF2YkhJdzlPdl9uQ3JnZGpNNDFqTmhRNk43a2pMMkptNUNsV2JVbk4xa0tYOHRjRDhsaWpPVWNCRGVsLUZKUUFzaFpaSEFxTHQ0aG5tTVVSdm44dlBGZnFPOG9Ea0RpVTRiTDhOam4?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxQXzVFelBtQlQ3MUdZMnhPOENxNmItNUZESHNzVHJvY1YydDI2WnpKYnp1VUlZUWliek1wQzZ2b0FiZ1MzbkVJZFZILTlCZHhJOExPeERDX3IzYlhLS1I4MTBKbmQzc0psZFlIOWZXelJhSlVTX0tuTVBTeVA3aHdLUUp4ZmRFb2hyX3NDSzlIOS1SSVpnOVVvMThLYml5Y1laRUszR3hQM3BjcGJqNFJfbk5JS1FIMGo3MEs1NWRobl9GZWVhMW5JVVh6UFVjcmZtdnhiaTJFOE1sSm03MkVvUlo4WkdKRU05UEE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxOUktxZ1FTOVB0cUZ5X19WZEx0Z2FhSzAtbFp2VDVYQU9EOS1nSUJ4anR6bTFmOXBXZWJ2aFhsV2NBV09ZRHhWVTVrejZYam5idmJNRnhNSURKN3RzYU1BR1lLTmpHTFg4Z0M4Yi1uN1gxWHllWFFzTHJzR3gtanp3cXZSbE5PMkVYNDFzaU9DVTJYMU5sQkw5T2dKRG1vbHd4ekU4UWFaUEcwdnJJSHp1QngxY284cS1DMTNRS2hQQ2VBeHM4RnhNZzJxMk5pYW1KZHFUa3hyOXl3bWUtZXVfQ0dMekZRaFJFVVRHQ2dnbGQ2YU51em9RbGhDbjQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aurum holds 5,001,561 shares in Polypid Ltd. (PYPD) with exercisable warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPQlBiX0Z5WWMycWtMQjJfTVJVaWR4ZVBlczRHMVFTckt2SzBmY282Ykg0OEd5dkRjOXAtNXVZdU1uUHdId2NVQnVBWklJNHEyUXJROXlsMzBLUVhqUmY5QkR0YlFwdmdvRmhGdUZDMEFRX1lqUkh1Rk5GaktIbFNKSHBsYWVFS0NUUEFlanF4ckhjUUhqVVl2a1BOYzZvYUU1aGlaV21SQ3pvNkJ4WjlxZWZjdGtRQ3RZSjl3LXZMS3hGTHA4bGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Will PolyPid Ltd. (NASDAQ:PYPD) Turn A Profit?", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBBTTdlZFNRVkdsQk9JQnpPQ0JNeXpVd09YaWJhQ2R2SVdvNC1pd1F3UkFUbGkzNUUxTUhZMWNTRmpKVTRRZUw1ZlB3NlJ2X1hKU3R6MnZvdjkzeEJMVWZXQWFtenNNaUxtQThLdDJpTGdOY2RsOWVVNlFOZGFoRmM?oc=5", "source_name": "Market source", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is PolyPid (NASDAQ:PYPD) A Risky Investment?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-28T07:00:00+00:00", "published_display": "28 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analyst Says PolyPid is a Buy with 300% Potential Upside as it nears Phase 3 Data Readout", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxQSVlQM2VrM192NnRnWmNhdEFzTFEyMzE1eDlQWlhqb3paWXliY1ZwWUJyQUw1dFVCWlVDR0xfRlpOemxCZG9pb3JJbEpGWUM2dVdFZk5DSlUtWjkzVzFsNURQY2dpQjc2R0dLdlVtY01qS29oYW9jMkotTUlZVzlWN18xdk0yZjlONXZVdWRrM3lQelpoYVB0X1NnWUxrNFB6czlvQzVZcFlxMVROMzlDVGRFbjZuQk52VElXelR2bHdZVGoyRWF2Z2pleDJGX05PQnBTVWw1YjVTUjFwMFBqYU9URHgzc2dNRVFR?oc=5", "source_name": "newsblaze.com", "published_at": "2025-06-02T07:00:00+00:00", "published_display": "02 Jun 2025 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PolyPid (PYPD) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE84ZklLRnF5QkdlMW5WUEFpaGN6anF5WEJFRHI4OHlOa3FxN0hGYURWWUk1T1d6NlprQWVfd2RMQkxOQU5JaTllNmluZy1tNjJWNnoxUlEwQmRxdw?oc=5", "source_name": "MarketBeat", "published_at": "2020-07-21T12:59:37+00:00", "published_display": "21 Jul 2020 12:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 53, "sentiment_summary": {"positive": 12, "negative": 3, "neutral": 38, "score": 54, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 12.65, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 12.65, "count": 25}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 5.23, "latest_week": "2026-07-10", "one_week_move": 4.2, "four_week_move": 13.2, "twelve_week_move": 10.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.885996, "market_dynamics_buy_signal": false, "relative_strength": 10.176452, "fair_value_gap": 20.9, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.7423, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.2% over one week, +13.2% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingKey", "count": 8}, {"label": "Market source", "count": 7}, {"label": "TradingView", "count": 7}, {"label": "Stock Titan", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Quartr", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 25}, {"label": "Market update", "count": 23}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+4.2% over one week, +13.2% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "PolyPid Ltd. (PYPD) boosts option pool by 1.5M shares and clears CEO grant"}], "updated_at": "2026-07-16T14:29:24.161726+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}